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Immunotoxicology in the
Pharmaceutical Industry
by Kenneth C. Norbury*
Development of an immunotoxicology program within the pharmaceutical industry is
described. With few guidelines in this area and a multitude offactors to consider, a basic screen
for evaluating immune competence in species routinely used in toxicologic studies has been
proposed. The future of immunotoxicology depends upon the ability of the selected immune
function tests to be predictive of human risk.
The use of immunologic methods over the past
several decades has been important in the devel-
opment of anti-inflammatory drugs. However, the
application of immunology within a toxicology
environment has only occurred relatively recently.
The Immunotoxicology Program at Merck Sharp &
Dohme Research Laboratories (MSDRL) has orig-
inated within the Department of Safety Assess-
ment. I would like to review the development of
this program since its inception three years ago.
Since our program is still in its infancy, I must
emphasize this paper represents many of my
opinions based on the state-of-the-art and future
application of immunotoxicology as I perceive
them. Because there remains a considerable amount
of characterization and refinement of our immune
function tests, we do not intend to test new drug
candidates until the utility of the procedure is
proven.
Historical Perspective
In 1977 there were few guidelines regarding
immunotoxicologic testing. The European Economic
Community (EEC) drafted the following purpose
ofimmune function tests in the fall ofthat year: (1)
to evaluate the potential risk of the drug by
determining the functional significance ofthe effect
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on lymphoid organs found in routine toxicity stud-
ies; (2) to obtain more insight into the mode of
action (i.e., which cell type is the target and which
phase ofthe immune response is impaired).
At first, this may seem to be a reasonable
attempt to acknowledge the importance of im-
munologic testing, but I call to your attention one
particular paragraph in these proposed guidelines:
At the termination of a toxicity study, thymus, spleen,
and lymph nodes should be weighed and examined
microscopically. From these data and measurements of
serum immunoglobulin fractions and counts ofcirculating
lymphocytes, the conclusion should be reached whether
the substance has an effect on the lymphoid system and
whether or not specific function tests have to be per-
formed.
The intent, then, is for immune function tests to
be done only after histopathologic and hematologic
studies have been performed. There are some
important pitfalls to this approach. The first is that
histopathologic changes are not a sensitive indica-
torofdrug-inducedimmunologictoxicity. Generally,
histomorphologic changes associated with compro-
mised immune function are seen only at fairly high
dosage levels. In addition, the inability to differen-
tiate morphologically between T-cells and B-cells
is well known. Serum immunoglobulin fractions
are equally insensitive as indicators of immune
function. They represent an immune response that
occurred early in life and are not representative of
immune competence in older individuals. The cir-
culating leukocyte count and differential, while
53admittedly important in determining immune com-
petence, could be misleading if absolute numbers
are within the normal range. The function of these
cells might still be impaired.
None of these tests, with the possible exception
of serum immunoglobulin levels, really measures
immune function. Yet the EEC guidelines did
recommend that certain immune function tests be
done, patterned after the review by Vos (1). The
scope of these assays involves in vivo and in vitro
testing of cell-mediated immunity (CMI), humoral
immunity (HI) and phagocytosis by macrophages.
As we shall see later, this approach needs to be
tempered to meet the needs of conventional toxic-
ity studies.
Factors That Influence
Immunotoxicological Testing
A standard operating procedure in toxicology
includes total leukocyte counts and differential,
measurement of organ weights (such as adrenal
and spleen), and histologic examination of lym-
phoid organs (spleen, thymus, lymph nodes, and
bone marrow). Certain immune function tests
would then have to be added to the conventional
study in order to make a valid interpretation of
immunotoxicologic effects. The panel discussion at
the Gordon Conference on Toxicology and Safety
Evaluations in August of 1978 did a great deal to
prioritize the kinds of determinations that need to
be done and which function tests are appropriate
to do. On the other hand, some laboratories have
proposed a more extensive and perhaps idealistic
approach. MSDRL has elected to pursue an approach
which applies the most current knowledge of
immunology in a practical way.
There are many considerations which tend to
complicate an analysis of immune competence.
Dosage level and frequency are important vari-
ables to consider. Low dosage levels may enhance
an immune response whereas higher dosage levels
may be immunosuppressive. Whether a drug is
administered as a single or multiple dose, as well
as the route of administration, will contribute to
the effect observed. Furthermore, it is important
to correlate immune function tests with the dosage
regimens used. All too frequently, substantially
different protocols are used to measure CMI and
HI, with particular reference to the time of
administration of the test compound with respect
to the time the immunologic stimulus (antigen) is
introduced. Consequently, any differences between
immune responses are not easy to interpret. Final-
ly, the age of the animals being tested is particu-
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larly critical from an immunologic standpoint. The
prenatal period, early postnatal period and late
adulthood may be especially vulnerable to im-
munologic alterations. In fact, there does appear
to be a natural loss of immunoreactivity with age
(2).
Another factor would be the species employed
for immunologic testing, taking into consideration
drug metabolism. For example, the difference in
the LD50 between mice and rats for cyclopho-
sphamide (3) most likely represents differences in
metabolism to the reactive intermediate. One fun-
damental difference between routine toxicologic
evaluation and basic research in immunology is the
use of random-bred versus inbred strains, respec-
tively. Random-bred strains may accentuate ani-
mal-to-animal variation, especially since many
immune responses are under genetic control (4).
The adaptation of universally accepted assays in
one species (i.e., mouse) to a species typically used
in toxicology (e.g., rat) requires adequate charac-
terization. For instance, one should not assume
that a B-cell mitogen (lipopolysaccharide) in the
mouse is automatically a B-cell mitogen in the rat.
Secondary factors resulting from stress-related
phenomena (i.e., adrenocortical hypertrophy) can
also lead to immunologic changes. Other important
considerations include the relative sensitivity of
immunologic assays, method of calculation, corre-
lation of in vivo and in vitro findings, differences
between sexes, production of delayed or biphasic
immunobiologic responses, presence of contami-
nants in the feed or drinking water and the length
of the study.
The ultimate proof of an immunologic evaluation
is the ability to predict human risk. One of our
most frequently asked questions is: what does it
mean if the hematologic, serum biochemical and
gross and histopathologic examinations show no
effect due to treatment, but an immune function
test indicates an alteration? The answer, ofcourse,
depends upon the predictability of the immune
function test. A more pragmatic approach might
be to ask whether a given compound will cause
hypogammaglobulinemia, alter the state of hyper-
sensitivity to pollens, food or contact allergens,
increase susceptibility to infection, alter comple-
ment activity or induce an autoimmune reaction,
all of which are highly relevant questions regard-
ing human risk. Indeed, determination of serum
immunoglobulin levels, induction of delayed-type
hypersensitivity reactions in skin, quantitation of
specific antibody titers, determination of lympho-
proliferative potential, and enumeration of T- and
B-cells form the basis of clinical immunology.
It is important to recognize that the evaluation
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siveness and is not simply the examination of
lymphoid tissue at a single point in time using
histopathologic techniques and hematology. Four
steps of the immune response that may be altered
by drugs are: (a) the recognition of antigen, (b)
clonal proliferation, (c) differentiation and (d) the
effector phase, characterized by the infiltration of
immune cells into the site of an immunologic
reaction and the secretion of lymphokines, induc-
tion of delayed hypersensitivity, graft rejection,
and/or elaboration of specific antibodies. Drugs
that block contractile microfilaments, such as
cytochalasin B, might be expected to interfere
with the antigen processing by macrophages. The
majority of antineoplastic drugs are known to
interrupt the proliferative phase of lymphocytes
by blocking DNA synthesis.
In summary, the scope of any immunotoxicology
program should be to develop tests that can
reliably, efficiently, and inexpensively screen a
large number of compounds for their ability to
modify the immune response. Because of the
complexity ofthe immune system, a panel oftests,
both in vitro and in vivo must be used. Testing
should proceed in basically two phases: simple,
straightforward assays that are capable of detect-
ing major alterations in the immune response
(such as antibody production to a T-dependent
antigen which requires helperT-cells, macrophages,
and B-cells) followed by more complicated proce-
dures (specific immune models) that elucidate mech-
anisms of drug actions and identify cell types.
Development of an
Immunotoxicology Program
At MSDRL we started with the assumption that
the evaluation of immune competence would be
performed during a routine toxicity study. This
approach offers several advantages, including the
coordination of immunologic tests with other toxi-
cological parameters (i.e., hemotology, serum bio-
chemistry, and histopathology), collection of mul-
tiple blood samples, potential to build a large
historical data base and detection of novel immune
modulators that would not have otherwise gone
through an immunologic screen. However, before
immunotoxicology can begin to pay dividends,
progress will need to be made in some areas, such
as increasing our understanding ofthe mechanisms
involved in the immune response, adapting immu-
nologic methods from one species to another to
obtain interspecies correlation of data, arriving at
a consensus on which assays should be performed
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and accepting a multifaceted approach to delineate
the mechanism of drug action (not necessarily in
that order).
Originally, three fundamental immunologic func-
tion areas were designated. The primary objec-
tives were to select tests that could be done in
rats, dogs, and monkeys and would interface with
the standard operating procedures of our laborato-
ry, such as the collection of blood samples at the
same time as routine bleedings for hematologic
and serum biochemical studies.
Serum Immunoglobulin Levels
The quantitation of serum immunoglobulin lev-
els, specifically IgG, IgM, and IgA, was chosen as
a crude reflection of B-cell activity. Since we usu-
ally analyze a relatively large volume ofsamples in
a day, it was apparent that many of the currently
available techniques to quantitate specific serum
proteins (i.e., radial immunodiffusion, radioimmu-
noassay, and electroimmunodiffusion) were unsuit-
able because of lack of automation. Another initial
requisite, commercially available reagents, also was
not feasible at that time; reagents were available
to quantitate human serum immunoglobulins, but
not for rats, dogs, and monkeys. We chose to
produce monospecific, high avidity antibodies from
goats directed against IgG, IgM and IgA from all
three species and to use the nephelometric technol-
ogy developed by Ritchie (5). This highly sensitive
method is capable ofdetecting the microprecipitate
formed from an antigen (IgG, IgM, or IgA)-antibody
reaction. Other automated systems are becoming
available and we are in the process of evaluating
them for the purpose of quantitating serum immu-
noglobulins.
Lymphocyte Blastogenesis
Perhaps one ofthe most universal assays used in
immunology today is the induction of lymphocyte
proliferation with mitogens or specific proteins,
also known as the transformation or blastogenic
assay. Certain plant lectins, such as concanavalin
(ConA) and phytohemagglutinin (PHA) selectively
stimulate T-cells to undergo DNA synthesis in a
polyclonal fashion. On the other hand, bacterial
products, such as lipopolysaccharide, polyclonally
stimulate B-cells (at least in the mouse). The search
for a potent B-cell mitogen in other species is still
continuing: Mycoplasma neurolyticum appears to
be a B-cell mitogen in the rat (6).
From information available in the murine sys-
tem we developed a blastogenic assay in the rat.
In order to interface with our current standard
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FIGURE 1. Protocol forthe lymphoproliferative response ofrat peripheral blood cells by mitogens.
operating procedures, we modified the whole blood
assay described previously by Han and Pauly (7)
(see Fig. 1). At the same time that the hemotologic
sample was taken, a sample for the blastogenic
assay was obtained. After a standard dilution, the
cells were cultured with the appropriate mitogen
and the functional activity of the respective popu-
lations of lymphocytes was assessed. During the
course of development, we considered whether or
not additional nutrients, such as fetal calf serum or
mercaptoethanol, should be used to supplement
the media. The addition of these supplements did
not increase the magnitude of the responsiveness
sufficiently to warrant their use (Norbury, unpub-
lished findings). In addition, it was reasoned that
by adding them, any immunopotentiating effect
might be masked.
With this technique we were able to show immu-
nosuppressive activity with cyclophosphamide (8)
and dexamethasone but not with aspirin (Table 1).
Table 1. Mitogen-induced proliferative responses of rat peripheral blood cells in vitro following various treatments in vivo
Relative proliferation indexa
Number of Concanavalin A Phytohemagglutinin Pokeweed mitogen
lymphocytes, (2-4 (0.32-0.64 (1.6-3.2 (6.4 (1.6-6.4 (1.6-6.4
Treatment group % of control ,ug/well) ,ug/well) ,ug/well) ,ug/well) ,ug/well) ,ug/well)
Purification by dextran-citrateb - + - + - +
Cyclophosphamide (n = 8)C
10 mg/kg 81 0.59* 3.29 0.44* 1.50 0.70 1.41
50 mg/kg 32 0.02* 0.70 0.04* 0.48* 0.13* 0.39
Dexamethasone (n = 8)d
0.35 mg/kg 43 0.08* 1.48 0.05* 0.88 0.17* 1.03
0.70 mg/kg 41 0.01* 1.68 0.06* 0.99 0.15* 1.77
Aspirin (n = 5)e
100 mg/kg/day 111 0.94 NT NT NT NT NT
200 mg/kg/day 123 0.84 1.96f NT NT NT NT
*Significantly different from controls (p S 0.05) using anti-rankit transformation.
aRelative proliferation index is calculated from the following formula: mean counts per minute (treated)/mean counts per minute
(controls) at the optimal concentrations (indicated in parentheses) for each mitogen. NT = not tested.
bLymphocytes were collected from the buffy coat and plated at a concentration of 105 cells per well in 96-well microtiter plates.
CAnimals were given a single oral dose; peripheral blood was collected from the retro-orbital plexus 4 days later.
dAnimals were given a single oral dose; blood was collected 2 days later.
eAnimals were dosed orally for 30 days and then bled.
'Lymphocytes were depleted of erythrocytes by ammonium chloride lysis.
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an antigenic stimulus ofthe animal is not required,
thus eliminating the need to manipulate animals in
a manner that may jeopardize the integrity of the
routine toxicological evaluation. However, one im-
portant disadvantage ofthis technique is not know-
ing the fate of the lymphocyte once it is cultured.
In the case ofcyclophosphamide, a slight reduction
(19%) in the number of circulating lymphocytes
caused a significant suppression of the lymphopro-
liferative response to both ConA and PHA. At
higher doses, cyclophosphamide caused marked lym-
phopenia with concomitant reduction in the lym-
phoproliferative response. It was entirely possible
that the blastogenic assay was merely a reflection
of the number of immunocompetent cells in cul-
ture. However, when the number of lymphocytes
separated by dextran-citrate was adjusted to a
constant concentration based on viability, the resid-
ual lymphocytes from cyclophosphamide-treated ani-
mals still had significantly impaired responsiveness
to PHA (Table 1). Better techniques will be needed
to determine if the lymphocytes from treated ani-
mals are still viable after 5 days in culture, espe-
cially when using a whole blood preparation.
Enumeration of Lymphocyte
Subpopulations
In the event that an immune function test dem-
onstrates impairment, it behooves the investigator
to determine the number ofimmunocompetent cells.
Lymphocyte subpopulations can generally be clas-
sified into three broad categories: T-cells, B-cells,
and null cells. It is now known, particularly with
the T-cell population, that a variety of subsets (T
helper, T suppressor, T killer, etc.) exists and the
means to quantitate them needs to be seriously
considered. Once again, various methods are avail-
able, including immunofluorescence, rosette forma-
tion, histochemistry, cell electrophoresis, cytolysis
and fluorescence-activated cell sorting. Immuno-
fluorescence is the most popular technique, espe-
cially in working with rodents. The rosette forma-
tion assay appears to have some limitations when
working with species other than human and is
prone to interlaboratory variation. Histochemical
methods also have limited application aside from
human studies and cell electrophoresis is too ana-
lytical for immediate use. The complement-de-
pendent, antibody-mediated cytolytic test can be
used for quantitating lymphocyte subpopulations
oflymphocytes on a routine basis. (I am not imply-
ing that none of the other methods can or will
eventually be modified for routine testing.) With
commercially available rabbit anti-rat thymocyte
serum plus complement we obtained approximately
90% lysis of rat thymocytes and 50-55% lysis of
splenic lymphocytes usingthe Coultercounter. The
application of this particular technique to other
peripheral organ sources (lymph node and periph-
eral blood) has not been as fruitful. Obviously much
more work is needed in this area.
From this three-part program, the concept of a
Table 2. Special follow-up studies using common immune models.
Cell-mediated immunity
Humoral immunity
Reticuloendothelial system
Resident/recruited alveolar and peritoneal cells
Polymorphonuclear leukocytes
Other
Study
Memory (secondary antigen exposure)
Lymphocyte mediated cytotoxicity
Mixed lymphocyte reaction
Lymphokine production
Antibody response to T-independent antigen
Memory
Plaque-forming cell quantitation
Number
Phagocytosis
Response to lymphokines
Cytotoxicity
Chemotaxis
Enzymatic activity
Mast cell degranulation
Chemotaxis
Phagocytosis
Immunopathology
Stem cell colony formation
Complement activity
Antinuclear antibodies
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ber of assays that would allow a meaningful inter-
pretation of immunologic alterations. The basic
screen includes the determination of total serum
IgG, IgM and IgA, blastogenesis with T- and B-cell
mitogens as well as specific antigens, cell enumer-
ation, total leukocyte and differential, delayed type
hypersensitivity, primary antibody responses to a
T-dependent antigen, clearance of particulate mat-
ter by the reticuloendothelial system, and histopa-
thology. This satisfies most of our initial criteria
for evaluating T-cell and B-cell responses as well
as macrophages while keeping the number ofassays
to a minimum. Such assays are relatively simple to
perform and the technology now exists to imple-
ment them. However, it does appear that we may
have to include additional animals that would not
necessarily be processed as part of the routine
toxicity study.
Until disproven, my bias is that the evaluation
of antibody titers to a T-dependent antigen will
eventually represent the best single analysis, closely
simulating the immune response to infection. An
antibody assay is quite sensitive and represents a
response to a defined antigen involving the same
types of cells that mediate immunity to infection.
In the event that the basic screening reveals
alterations or inadvertent modifications of the im-
mune response, special follow-up studies (Table 2)
can be carried out to clarify the mechanism of
action and the cell types involved, with particular
emphasis on defining the subpopulations affected
by the drug. Nevertheless, it is important to under-
stand the limitations of any assay before making a
judgment regarding the effect of a drug on the
immune response.
Future of Immunotoxicology
In addition to on-line testing, there are other
areas where immunology can be applied within the
pharmaceutical industry.
Skin Sensitization
New developments in the methodology used to
evaluate drug-induced hypersensitivity, or skin
sensitization, has made it possible to improve the
credibility of certain obligatory tests. The Land-
steiner-Draize guinea pig skin test has long been
the method of choice for doing skin sensitization.
However, the development of the skin maximiza-
tion test (9) has greatly improved the predictabil-
ity of the guinea pig model while eliminating false
negatives.
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Development of Biologicals
Some pharmaceutical companies are actively de-
veloping viral vaccines as well as other adjuvants.
Immunotoxicology would offer a dimension beyond
that capable of routine toxicology for the assess-
ment of potential adverse effects that might be
immunologically mediated.
Development of Specific Immune
Modulators
While the search for new and better anti-inflam-
matory compounds is an active program of many
institutions, the toxicological examination of these
new product candidates, inclusive ofimmune func-
tion testing, offers a broader basis for determining
the potential of that particular drug.
New Product Development
The toxicologic testing of compounds that are
not specifically designed as immune modulators may,
in remote instances, demonstrate immunologic en-
hancement or impairment. Such information could
then be referred back to medicinal chemists and
pharmacologists for further development.
Basic Research
To aid in the development of more rapid and
reliable assays as well as new immune models,
which are critical to understanding the effects of
chemicals on the immune response, some effort
should be made in an immunotoxicology program
to conductbasic research.
Conclusion
The field of immunotoxicology is in the early
stages ofrapid development. Although the immune
response is quite complex, involving a sophisticated
array of cellular and molecular interactions, there
is increasing evidence that chronic, subclinical expo-
sure to a variety of chemicals does in fact lead to
an adverse modification of immune function, mani-
fested most ostensibly by reduced host resistance
to infectious agents, such as viruses and bacteria
(10). In many respects, the state-of-the-art is much
like mutagenesis was five to ten years ago. Yet we
must realize that the progress ofimmunotoxicology
will depend upon the continued, close interaction
among persons in academia, industry, as well as
governmental institutions. With the approach evolv-
ing at MSDRL, it now seems possible to move
ahead in this area. Ultimately, a basic screen for
Environmental Health Perspectivesimmune competence needs to be validated using
compounds with known immunosuppressive effects
as part of a subacute study. In doing so, one must
be prepared to explain any alteration in immune
function in the absence of overt toxicity as typi-
cally described by physical observation, hemato-
logical and serum biochemical studies, urinalyses,
and gross and histomorphologic examination. With
furtherdevelopmeiat, immunotoxicology can become
part of the repertoire of toxicity testing, as we
have seen for teratology and mutagenicity.
The author recognizes the excellent technical assistance ren-
dered by Mr. C. Noble and wishes to thanks Ms. J. Arizin for
typing the manuscript and Drs. J. S. MacDonald and A. E.
Munson for their valuable comments.
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